Previous 10 | Next 10 |
2023-06-02 17:22:22 ET Gainers: Lyra Therapeutics ( LYRA ) +13% . Hibbett ( HIBB ) +4% . Infinera Corporation ( INFN ) +3% . Gladstone Commercial ( GOOD ) +3% . Aclaris Therapeutics ( ACRS ) +2% . Losers: Trupanion ...
WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in two hea...
2023-05-08 11:56:02 ET Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Conference Call May 08, 2023, 8:00 AM ET Company Participants Robert Doody - Head of Investor Relations Douglas Manion - Chief Executive Officer Gail Cawkwell - Senior Key Executive Jos...
2023-05-08 10:03:22 ET Gainers: Immuron ( IMRN ) +49% . ANI Pharmaceuticals ( ANIP ) +17% . MiNK Therapeutics ( INKT ) +13% . Evaxion Biotech ( EVAX ) +8% . Predictive Oncology ( POAI ) +8% . Losers: Catalent ( CTLT ) ...
2023-05-08 07:03:04 ET Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q1 GAAP EPS of -$0.42 beats by $0.02 . Revenue of $2.53M (+74.5% Y/Y) beats by $0.78M . The increase was driven by higher licensing revenue primarily from royalties earned on out-licens...
- Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announ...
2023-05-05 12:16:05 ET Aclaris Therapeutics ( NASDAQ: ACRS ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is -$0.44 (-41.9% Y/Y) and the consensus Revenue Estimate is $1.75M (+20.7% Y/Y). Over the last ...
2023-05-05 11:40:34 ET Major earning expected before the bell on Monday include: BioNTech ( BNTX ) DISH Network ( DISH ) KKR & Co. ( KKR ) Tyson Foods ( TSN ) Viatris ( VTRS ) For further details see: Notable earnings before Monday's open
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, M...
2023-04-24 14:37:47 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D. But debt-fueled spending is becoming expensive. And selling sto...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...